Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need.
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma
Larocca, Alessandra;
2021-01-01
Abstract
Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
[PUBLISHED Vsn.] Richardson et al - 2020 - jco.20.02259.pdf
Accesso aperto
Descrizione: [PUBLISHED Vsn.] Richardson et al. J Clin Oncol . 2021 Mar 1;39(7):757-767. doi: 10.1200/JCO.20.02259. PMID: 33296242. © 2021 American Society of Clinical Oncology. All rights reserved. Available at / disponibile all’URL: https://ascopubs.org/doi/10.1200/JCO.20.02259 | https://doi.org/10.1200/jco.20.02259
Tipo di file:
PDF EDITORIALE
Dimensione
446.35 kB
Formato
Adobe PDF
|
446.35 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
